Technological advances in hybrid imaging and impact on dose

Radiation Protection Dosimetry165(1–4), 410–415 (2015).

The headings of Tables 2 and 3 have been reversed. The following shows the correct version:

Table 2.

The PET-contribution to the effective dose to patients at typical PET/CT investigations⁽⁵⁾.

Study	Radionuclide	Pharmaceutical	Activity, MBq	Effective dose, mSv
Tumour	18F	FDG	300–400	4.8–6.4
Tumour	18F	Choline	300	5.5
Bone	18F	Fluoride	300	4.0
Tumour	11C	Choline	300	1.2
Alzheimer	11C	PiB	300	1.0
Tumour	11C	Acetate	400	1.7
Tumour	11C	Methionine	800	4.4

Table 3.

The SPECT-contribution to the effective dose to patients at typical SPECT/CT investigations⁽⁵⁾.

Study	Radionuclide	Pharmaceutical	Activity, MBq	Effective dose, mSv
Bone	99mTc	Phosphonates	600	2.6
Myocardial perfusion	99mTc	Tetrofosmin; sestamibi	600	3.6
Brain	99mTc	HMPAO	800	8.1
Tumour	123I	MIBG	400	5.3
White cell	111In; 99mTc	In vitro labelled leukocytes	18; 185	5.1; 1.3